A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma.
Emily HoLoris De CeccoStefano CavalieriGeoffrey SedorFrank HoebersRuud H BrakenhoffKathrin ScheckenbachTito PoliKailin YangJessica A ScarboroughShauna CampbellShlomo KoyfmanSteven A EschrichJimmy J CaudellMichael W KattanLisa LicitraJavier F Torres-RocaJacob G ScottPublished in: medRxiv : the preprint server for health sciences (2023)
In this multi-institutional cohort of patients with HPV-positive OPSCC, GARD predicts OS as a continuous variable, outperforms the NRG nomogram and provides a novel genomic strategy to modern clinical trial design. We propose that GARD, which provides the first opportunity for genomic guided personalization of radiation dose, should be incorporated in the diagnostic workup of HPV-positive OPSCC patients.
Keyphrases
- squamous cell carcinoma
- clinical trial
- high grade
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- copy number
- lymph node metastasis
- peritoneal dialysis
- cervical cancer screening
- prognostic factors
- randomized controlled trial
- open label
- gene expression
- radiation induced
- double blind
- phase ii